vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
Dominari Holdings Inc. is the larger business by last-quarter revenue ($30.1M vs $28.1M, roughly 1.1× ARS Pharmaceuticals, Inc.). ARS Pharmaceuticals, Inc. runs the higher net margin — -147.1% vs -438.1%, a 291.0% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs -67.6%).
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
DOMH vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $28.1M |
| Net Profit | $-131.8M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | -8.9% | -147.6% |
| Net Margin | -438.1% | -147.1% |
| Revenue YoY | 220.4% | -67.6% |
| Net Profit YoY | -12426.2% | -182.8% |
| EPS (diluted) | $-6.94 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $28.1M | ||
| Q3 25 | $50.8M | $32.5M | ||
| Q2 25 | $34.1M | $15.7M | ||
| Q1 25 | $8.1M | $8.0M | ||
| Q4 24 | $9.4M | $86.6M | ||
| Q3 24 | $4.0M | $2.1M | ||
| Q2 24 | $6.2M | $500.0K | ||
| Q1 24 | $1.4M | $0 |
| Q4 25 | $-131.8M | $-41.3M | ||
| Q3 25 | $125.2M | $-51.2M | ||
| Q2 25 | $16.6M | $-44.9M | ||
| Q1 25 | $-32.5M | $-33.9M | ||
| Q4 24 | $1.1M | $49.9M | ||
| Q3 24 | $-4.2M | $-19.1M | ||
| Q2 24 | $-6.1M | $-12.5M | ||
| Q1 24 | $-5.4M | $-10.3M |
| Q4 25 | -8.9% | -147.6% | ||
| Q3 25 | -3.1% | -163.7% | ||
| Q2 25 | -57.0% | -302.9% | ||
| Q1 25 | -394.6% | -466.3% | ||
| Q4 24 | 0.4% | 54.5% | ||
| Q3 24 | -79.1% | -1051.6% | ||
| Q2 24 | -44.3% | -3068.0% | ||
| Q1 24 | -205.2% | — |
| Q4 25 | -438.1% | -147.1% | ||
| Q3 25 | 246.4% | -157.4% | ||
| Q2 25 | 48.7% | -285.6% | ||
| Q1 25 | -400.5% | -425.7% | ||
| Q4 24 | 11.4% | 57.7% | ||
| Q3 24 | -104.2% | -925.0% | ||
| Q2 24 | -99.1% | -2503.2% | ||
| Q1 24 | -398.0% | — |
| Q4 25 | $-6.94 | $-0.41 | ||
| Q3 25 | $7.27 | $-0.52 | ||
| Q2 25 | $1.12 | $-0.46 | ||
| Q1 25 | $-3.02 | $-0.35 | ||
| Q4 24 | $0.21 | $0.52 | ||
| Q3 24 | $-0.67 | $-0.20 | ||
| Q2 24 | $-1.01 | $-0.13 | ||
| Q1 24 | $-0.91 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $69.4M | $114.3M |
| Total Assets | $112.9M | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $245.0M | ||
| Q3 25 | $176.2M | $288.2M | ||
| Q2 25 | $28.2M | $240.1M | ||
| Q1 25 | $18.9M | $275.7M | ||
| Q4 24 | $8.2M | $314.0M | ||
| Q3 24 | $7.2M | $204.6M | ||
| Q2 24 | $12.1M | $218.7M | ||
| Q1 24 | $7.1M | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $69.4M | $114.3M | ||
| Q3 25 | $210.2M | $147.7M | ||
| Q2 25 | $88.6M | $192.3M | ||
| Q1 25 | $42.4M | $229.0M | ||
| Q4 24 | $39.9M | $256.8M | ||
| Q3 24 | $38.3M | $201.0M | ||
| Q2 24 | $42.4M | $215.2M | ||
| Q1 24 | $47.7M | $223.9M |
| Q4 25 | $112.9M | $327.7M | ||
| Q3 25 | $223.4M | $372.8M | ||
| Q2 25 | $109.3M | $313.5M | ||
| Q1 25 | $52.3M | $327.3M | ||
| Q4 24 | $47.1M | $351.2M | ||
| Q3 24 | $43.4M | $217.6M | ||
| Q2 24 | $49.1M | $222.0M | ||
| Q1 24 | $52.2M | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $-43.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $-43.5M | ||
| Q3 25 | $-4.9M | $-47.0M | ||
| Q2 25 | $-353.0K | $-39.6M | ||
| Q1 25 | $1.2M | $-40.7M | ||
| Q4 24 | $-16.7M | $42.0M | ||
| Q3 24 | $-4.7M | $-14.5M | ||
| Q2 24 | $1.4M | $-7.3M | ||
| Q1 24 | $-8.6M | $-6.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
